Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biomerica Inc. (BMRA:NASDAQ), powered by AI.
Biomerica Inc. is currently trading at $2.17. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Biomerica Inc. on Alpha Lenz.
Biomerica Inc.'s P/E ratio is -1.0.
“Biomerica Inc. trades at a P/E of -1.0 (undervalued) with modest ROE of -93.0%.”
Ask for details →Biomerica Inc. operates within the healthcare sector as a developer and manufacturer of advanced medical diagnostic products. The primary function of Biomerica Inc. is to innovate in the realm of diagnostic testing, with a focus on chronic diseases and conditions. Their portfolio includes products designed for the early detection and management of illnesses such as diabetes, gastrointestinal disorders, and various forms of cancer. Through its cutting-edge technology, Biomerica Inc. aims to improve patient care by offering precise and reliable testing solutions that can be utilized in clinical laboratories, hospitals, and research institutions. Biomerica's work significantly impacts the healthcare industry by catering to the rising demand for efficient diagnostic tools that help in timely disease intervention. Based in Irvine, California, and with a global presence, Biomerica Inc. positions itself as a pivotal player in enhancing healthcare delivery and contributing to clinical advancements by providing products that drive better health outcomes.
“Biomerica Inc. trades at a P/E of -1.0 (undervalued) with modest ROE of -93.0%.”
Ask for details →